Awarding a European prize is equivalent to a validation of the Technology readiness level (TRL) of the project by an independent body (EASME).
2017 H2020 SME INSTRUMENT phase-2 Topic :SMEInst-03-2017. European commission
2015 H2020 SME INSTRUMENT phase-1 Topic : BIOTEC-5a2015. European commission
2015 17th i-Lab “Créadev” BPI France
2013 15th “émergence” OSEO/BPI
2013 – Innovation Days One of 15 finalists “Innovation Prize” Universal Biotech.
Regulaxis is proud to present the recent results on the effectiveness of REG-O3 in a model of traumatic knee osteoarthitis.
“REG-O3 Chimeric Peptide combining Growth Hormone and Somatostatin sequences slows down Traumatic Knee Osteoarthritis Progression in Rat”
Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Yves Henrotin, Christelle Vêtu
Regulaxis’ President and CEO Claude Carelli and the CSO Christelle Vêtu participated to the OCT conference in Europe, in Milan, Italy, on May 14-15.
Follow us to http://regulaxis.com/news/
REGULAXIS is at the 2019 OARSI conference in Toronto from 2nd-5th of May !
OARSI World Congress on Osteoarthritis: Doctor Christelle Vêtu, CSO and Strategic Business Advisor will present the latest results during the poster session : “Chimeric Peptide combining both Growth Hormone and Somatostatin Sequences (REG-O3) improves function and prevents cartilage degradation in rat […]
REGULAXIS, a leader in peptide research and development, will presents its most recent preclinical data of REG-O3, an innovative chimeric peptide for the treatment of osteoarthritis of knee at the 2018 Osteoarthritis Research Society International World Congress (OARSI), to be held April 26-29, 2018 in Liverpool, UK.
Regulaxis is proud to present the recent results on the effectiveness of REG-O3 in a model of traumatic knee osteoarthitis.
ACCEPTED POSTER :
“REG-O3, new chimeric peptides regulating IGF-1 pathway: significant therapeutic effect on ACLT rabbit model of osteoarthritis”
Raffaello PAOLINI, Rodrick MONTJEAN and Christelle VETU